ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Neuromusculoskeletal Medicine OMM

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

13,306Medicare Part D Prescriptions Filled, Including Refills
$1.04M Total Retail Price of All Prescriptions
1,213 Patients Receiving at Least One Drug in Part D
68%Patients 65 Years and Older
4% Subsidized Claims for Low-Income Patients

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume .

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category
GABAPENTIN 1,917 1,321
DONEPEZIL HCL 1,196 1,142
LYRICA 749 330 10
SIMVASTATIN 619 439
TRAMADOL HCL-ACETAMINOPHEN 461 181
CYMBALTA 449 225
PLAVIX 441 339
CLOPIDOGREL 390 316
ZOLPIDEM TARTRATE 370 213
LEVETIRACETAM 369 253
EXELON 290 275
ETODOLAC 256 75
MAXIMUM D3 251 217 10
CARBIDOPA-LEVODOPA 248 216
ASPIRIN EC 246 185
TOPIRAMATE 231 93
NAMENDA 213 211
TRAMADOL HCL 213 75
CARVEDILOL 165 122
PRAMIPEXOLE DIHYDROCHLORIDE 162 162
PRIMIDONE 161 144
GALANTAMINE HBR 160 157
LAMOTRIGINE 150 55
PYRIDOSTIGMINE BROMIDE 140 110
SYNTHROID 131 86
OXCARBAZEPINE 130 93
QUETIAPINE FUMARATE 115 110
TRIHEXYPHENIDYL HCL 115 85 R
DEXAMETHASONE 109 53
CRESTOR 97 30
VYTORIN 86 58
ACETAMINOPHEN-CODEINE 78 31 S3
ATORVASTATIN CALCIUM 77 39
ARICEPT 76 76
DIPYRIDAMOLE 71 49 R
ENALAPRIL MALEATE 71 45
OMEPRAZOLE 69 41
ASPIR-LOW 67 50
SEROQUEL 67 63
CABERGOLINE 54 15
DIVALPROEX SODIUM 53 19
METFORMIN HCL 52 37
PREDNISONE 51 48
ASPIRIN 51 43
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on May 17, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.